| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | 46.218 | 37.108 | 49.553 | 189.533 | 199.121 | 259.783 | 301.303 | 420.217 | 1.572.673 |
| Total Income - EUR | - | 46.218 | 37.108 | 49.553 | 189.533 | 201.128 | 259.835 | 302.028 | 432.690 | 1.601.116 |
| Total Expenses - EUR | - | 1.612 | 5.157 | 15.822 | 63.576 | 84.777 | 96.020 | 149.567 | 349.450 | 1.130.413 |
| Gross Profit/Loss - EUR | - | 44.606 | 31.951 | 33.732 | 125.957 | 116.352 | 163.815 | 152.461 | 83.240 | 470.703 |
| Net Profit/Loss - EUR | - | 43.220 | 30.838 | 32.245 | 120.271 | 110.785 | 156.955 | 144.759 | 79.805 | 402.773 |
| Employees | - | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 6 |
Check the financial reports for the company - Oncopat Diagnostic Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | 0 | 0 | 990 | 1.443 | 2.578 | 208.028 | 337.624 | 615.880 | 570.243 |
| Current Assets | - | 45.238 | 78.102 | 34.514 | 124.959 | 111.513 | 223.543 | 198.053 | 247.858 | 419.055 |
| Inventories | - | 0 | 0 | 0 | 0 | 0 | 0 | 1.288 | 145 | 5.824 |
| Receivables | - | 2.814 | 591 | 1.323 | 52.673 | 2.448 | 1.956 | 6.162 | 73.466 | 112.915 |
| Cash | - | 42.424 | 77.511 | 33.191 | 72.286 | 109.064 | 221.587 | 190.602 | 174.247 | 300.316 |
| Shareholders Funds | - | 43.264 | 73.370 | 32.297 | 120.322 | 110.834 | 265.331 | 410.913 | 489.472 | 402.890 |
| Social Capital | - | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | 1.986 | 5.248 | 3.219 | 6.624 | 3.294 | 166.255 | 125.763 | 185.652 | 424.126 |
| Income in Advance | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 190.110 | 163.730 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Oncopat Diagnostic Srl